RBM10 and neoplasm: Interestingly, we observed that 92% of RBM10 alterations present in our EGFR-mutant tumor data set did not co-occur with a known EGFR TKI resistance–associated mutation such as EGFR T790M or C797S or MET gene amplification (Supplemental Figure 1B).